Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
NCT00001137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5982
Last updated 2013-12-06
Summary
The purpose of this study is to determine what combinations of anti-HIV drugs work best in patients treated over several years. The study will also assess the occurrence of side effects and opportunistic infections in patients with low viral loads compared to those with higher viral loads.
Conditions
- HIV Infections
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
lead NETWORK
Principal Investigators
-
Constance A. Benson, MD · Division of Infectious Disease, Antiviral Research Center, University of California, San Diego
-
Ann C. Collier, MD · University of Washington
Eligibility
- Min Age
- 13 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-01-31
- Primary Completion
- 2013-11-30
- Completion
- 2013-11-30
Countries
- United States
- Puerto Rico
Study Locations
More Related Trials
-
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
NCT00004582 ·Status: COMPLETED ·Phase: PHASE2
-
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
NCT00028301 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
NCT00004581 ·Status: COMPLETED ·Phase: PHASE3
-
Once-Daily Drug Regimen for HIV-Infected Patients
NCT00001968 ·Status: COMPLETED ·Phase: PHASE1
-
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
NCT00038532 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
NCT00851799 ·Status: COMPLETED
-
Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients
NCT01702090 ·Status: COMPLETED ·Phase: PHASE4
-
Atazanavir/Ritonavir Maintenance Therapy
NCT00084019 ·Status: COMPLETED ·Phase: NA
-
Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients
NCT00752037 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
NCT02473328 ·Status: COMPLETED ·Phase: PHASE2
-
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
NCT01605084 ·Status: WITHDRAWN ·Phase: PHASE3
-
Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
NCT02034838 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
NCT00002046 ·Status: COMPLETED ·Phase: NA
-
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir
NCT00458302 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
NCT00358917 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.
NCT01736761 ·Status: COMPLETED ·Phase: PHASE4
-
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
NCT00120393 ·Status: COMPLETED ·Phase: PHASE3
-
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
NCT00035932 ·Status: COMPLETED ·Phase: PHASE3
-
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
NCT01236235 ·Status: COMPLETED
-
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
NCT00110877 ·Status: COMPLETED ·Phase: PHASE3
-
Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
NCT00752856 ·Status: COMPLETED ·Phase: PHASE2
-
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
NCT00450580 ·Status: COMPLETED ·Phase: PHASE3
-
Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
NCT00118898 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
NCT00814879 ·Status: COMPLETED ·Phase: NA
-
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy
NCT00357552 ·Status: COMPLETED ·Phase: NA